Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: Interaction with low dose acetylsalicylic acid

British Journal of Clinical Pharmacology

Volumn 42, Issue 6, 1996, Pages 721-727

  Böger, Rainer H ^a   Bode Böger, Stefanie M ^a   Kramme, Petra ^a   Tsikas, Dimitrios ^a   Gutzki, Frank M ^a   Frölich, Jürgen C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

angiotensin converting enzyme inhibitors; bradykinin; cyclic GMP; endothelium

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; ANGIOTENSIN I; CAPTOPRIL; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN E2; THROMBOXANE A2;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INTERACTION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; RANDOMIZED CONTROLLED TRIAL;

EID: 0029853488     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.00480.x     Document Type: Article

References (40)

1. Burris JF. The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J Clin Pharmacol 1995; 35: 337-342.
2. Yang HYT, Erdos EG, Levin Y. Characterization of a dipeptide hydrolase (kininase II: angiotensin converting enzyme). J Pharmacol Exp Ther 1971; 177: 291-300.
3. Furchgott RF. Role of the endothelium in responses of vascular smooth muscle. Circ Res 1983; 53: 557-573.
4. Abe K, Itoh T, Imai Y, et al. Application of endogenous prostaglandin system in the antihypertensive effect of captopril, SQ 14225, in low renin hypertension. Jpn Circ J 1980; 44: 422-425.
5. Vanhoutte PM, Auch-Schwelk W, Biondi ML, Lorenz RR, Schini VB, Vidal MJ. Why are angiotensin-converting enzyme inhibitors vasodilators? Br J Clin Pharmacol 1989; 28: 95S-103S.
6. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclo-oxygenase inhibition. Circulation 1985; 72: 1177-1184.
7. Düsing R, Scherhag R, Landsberg G, Glänzer K, Kramer HJ. The converting enzyme inhibitor captopril stimulates prostacyclin synthesis by isolated rat aorta. Eur J Pharmacol 1983; 91: 501-504.
8. Scherf H, Pietsch R, Landsberg G, Kramer HJ, Düsing R. Converting enzyme inhibitor ramipril stimulates prostacyclin synthesis by isolated rat aorta: Evidence for a kinin-dependent mechanism. Klin Wochenschr 1986; 64: 742-745.
9. Harding P, Stonier C, Aber GM. Dose-dependent effects of angiotensin converting enzyme (ACE) inhibitors on glomerular prostanoid production by normotensive rats. Br J Pharmacol 1993; 108: 327-330.
10. Hoffmann G, Pietsch B, Göbel O, et al. Converting enzyme inhibition and vascular prostacyclin synthesis: effect of kinin receptor antagonism. Eur J Pharmacol 1990; 178: 79-83.
11. Graf K, Bossaller C, Auch-Schwelk W, Gräfe M, Baumgarten CR, Fleck E. ACE-inhibitors diminish the degradation of bradykinin and enhance endothelium-dependent relaxations in isolated coronary arteries. Pharm Pharmacol Lett 1991; 1: 71-73.
12. Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG, Moore TJ. Captopril-induced changes in prostaglandin production. Relationship to vascular responses in normal man. J Clin Invest 1980; 65: 1257-1264.
13. Silberbauer K, Stanek B, Templ H. Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition. Br J Clin Pharmacol 1982; 14: 87S-93S.
14. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-1177.
15. Hajj-ali AF, Zimmermann BG. Nitric oxide participation in renal hemodynamic effect of angiotensin converting enzyme inhibitor lisinopril. Eur J Pharmacol 1992; 212: 279-281.
16. Cachofeiro V, Sakakibara T, Nasljetti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension 1992; 19: 138-145.
17. Wennmalm A, Benthin G, Edlund A, et al. Metabolism and excretion of nitric oxide in humans. Circulation 1993; 73: 1121-1127.
18. Böger RH, Bode-Böger SM, Gerecke U, Frölich JC. Long-term administration of L-arginine, L-NAME, and the exogenous NO donor molsidomine modulate urinary nitrate and cyclic GMP excretion in rats-correlation with vascular reactivity. Cardiovasc Res 1994; 28: 494-499.
19. 3- excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-NAME in rats. Clin Exp Pharmacol Physiol 1996; 23: 11-15.
20. Bode-Böger SM, Böger RH, Schröder EP, Frölich JC. Exercise increases systemic NO production in man. J Cardiovasc Risk 1994; 1: 173-178.
21. Bode-Böger SM, Böger RH, Creutzig A, et al. L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci 1994; 87: 303-310.
22. Böger RH, Bode-Böger SM, Gutzki FM, Tsikas D, Weskott HP, Frölich JC. Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man. Clin Sci 1993; 84: 517-524.
23. Böger RH, Bode-Böger SM, Schröder EP, Tsikas D, Frölich JC. Increased prostacyclin production during exercise in untrained and trained man: effect of low-dose aspirin. J Appl Physiol 1995; 78: 1832-1838.
24. Fisher LD, van Belle G. Multiple comparisons. In Biostatistics. A methodology for the Health Sciences, eds. Fisher LD, van Belle G. New York: Wiley 1993: 596-629.
25. Juillerat L, Nussberger J, Ménard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16: 564-572.
26. Auch-Schwelk W, Bossaller C, Claus M, Graf K, GrŠfe M, Fleck E. Local potentiation of bradykinin-induced vasodilation by converting-enzyme inhibition in isolated coronary arteries. J Cardiovasc Pharmacol 1992; 20 (Suppl. 9): S62-S67.
27. Lamontagne D, König A, Bassenge E, Busse R. Prostacyclin and nitric oxide contribute to the vasodilator action of acetylcholine and bradykinin in the intact rabbit coronary bed. J Cardiovasc Pharmacol 1992; 20: 652-657.
28. Koopmans PP, van Megen T, Thien T, Gribnau FWJ. The interaction between indomethacin and captopril or enalapril in healthy volunteers. J Intern Med 1989; 226: 139-142.
29. Oparil S, Horton R, Wilkins LH, Irvin J, Hammett DK. Antihypertensive effect of enalapril in essential hypertensionave: Role of prostacyclin. Am J Med Sci 1987; 30: 395-402.
30. Gerber JG, Franca G, Byyny RL, LoVerde M, Nies AS. The hypotensive action of captopril and enalapril is not prostacyclin dependent. Clin Pharmacol Ther 1993; 54: 523-532.
31. Witzgall H, Hirsch F, Scherer B, Weber PC. Acute haemodynamic and hormonal effects of captopril are diminished by indomethacin. Clin Sci 1982; 62: 611-615.
32. Bank AJ, Kubo SH, Rector TS, Heifetz SM, Williams RE. Local forearm vasodilation with intra-arterial administration of enalaprilat in humans. Clin Pharmacol Ther 1991; 50: 314-321.
33. Quilley J, Duchin KL, Hudes EM, McGiff JC. The antihypertensive effect of captopril in essential hypertension: Relationship to prostaglandins and the kallikreinkinin system. J Hypertens 1987; 5: 121-128.
34. Force T, Milani R, Hibbered P, et al. Aspirin-induced decline in prostacyclin production in patients with coronary artery disease is due to decreased endoperoxide shift. Circulation 1991; 84: 2286-2293.
35. Frölich JC, Wilson TW, Sweetman BJ, et al. Urinary prostaglandins. Identification and origin. J Clin Invest 1975; 55: 763-770.
36. van Wijngaarden J, Smit AJ, deGraeff PA, et al. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1994; 23: 240-245.
37. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20: 1549-1555.
38. Linz W, Wiemer G, Schölkens BA. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol 1992; 24: 909-919.
39. Hirooka Y, Imaizumi T, Masaki H, Ando S, Harada S, Momohara M, Takeshita A. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 1992; 20: 175-180.
40. 2 synthesis. Eicosanoids 1992; 5 (Suppl.): S60-S62.